Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.85 USD | +6.25% | -.--% | -29.17% |
Financials (USD)
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 2.81M |
---|---|---|---|---|---|
Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | - |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.11
x | P/E ratio 2024 * |
-0.12
x | Employees | 18 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.63% |
Latest transcript on Eloxx Pharmaceuticals, Inc.
1 day | +6.25% | ||
1 month | -3.41% | ||
3 months | -4.44% | ||
6 months | -22.73% | ||
Current year | -29.17% |
Managers | Title | Age | Since |
---|---|---|---|
Sumit Aggarwal
CEO | Chief Executive Officer | - | 21-03-31 |
Daniel Geffken
DFI | Director of Finance/CFO | 67 | 20-10-31 |
Ali Hariri
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Rubin
BRD | Director/Board Member | 63 | 14-04-30 |
Alan Walts
BRD | Director/Board Member | 64 | 21-03-31 |
Sumit Aggarwal
CEO | Chief Executive Officer | - | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.85 | +6.25% | 801 |
24-05-30 | 0.8 | +5.68% | 808 |
24-05-29 | 0.757 | -8.39% | 1,062 |
24-05-28 | 0.8264 | -2.78% | 1,887 |
24-05-24 | 0.85 | +6.25% | 5,213 |
Delayed Quote OTC Markets, May 31, 2024 at 03:55 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.17% | 2.81M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ELOX Stock